STEVEN W. WOHNOUTKA

Launched Lonsurf, Inqovi and Lytgobi: chemotherapies for metastatic colorectal/gastric cancer, MDS/CMML and an FGFR2 inhibitor for Cholangiocarcinoma, respectively.

• 2024 YTD Ranked #1 of 6 regions
• 2023 #1 RBD, Best Performers Club winner
• Increased YOY '23 -'24 business by 60%
• 2021-2023 long term incentive sales award winner
• 2022 Runner up Best Performers Club
• Only RBD to achieve =/>100% to goal for six consecutive quarters
• Effectively coached non-oncology experienced account managers to be top performers
• Nationally recognized for promoting the best culture by my national sales director
• Developed and nationally adopted key business analytics report to accurately determine true drug utilization
• Collaboration with marketing, training, drug access and medical affairs to effectively serve patients

Launched Lonsurf, Inqovi and Lytgobi: chemotherapies for metastatic colorectal/gastric cancer, MDS/CMML and an FGFR2 inhibitor for Cholangiocarcinoma, respectively.

• 2024 YTD Ranked #1 of 6 regions
• 2023 #1 RBD, Best Performers Club winner
• Grew YOY '23 -'24 business by 60%
• 2021-2023 long term incentive sales award winner
• 2022 Runner up Best Performers Club
• Only RBD to achieve =/>100% to goal for six consecutive quarters
• Effectively coached non-oncology experienced account managers to be top performers
• Nationally recognized for promoting the best culture by my national sales director
• Developed and nationally adopted key business analytics report to accurately determine true drug utilization
• Collaboration with marketing, training, drug access and medical affairs to effectively serve patients

Launched Xtandi and promoted Tarceva, an oral androgen receptor inhibitor for metastatic castrate resistant prostate cancer and an oral TKI, EGFR targeted therapy for NSCLC, respectively.

• 2024 YTD Ranked #1 of 6 regions.
• 2023 #1 RBD, Best Performers Club winner
• Grew YOY '23 -'24 business by 60%
• 2021-2023 long term incentive sales award winner
• 2022 Runner up Best Performers Club
• Only RBD to achieve =/>100% to goal for six consecutive quarters
• Collaboration with marketing, training, drug access and medical affairs to effectively serve patients
• Appointed to lead marketing resource utilization, patient advocacy initiatives and federal accounts.
• Developed and nationally adopted key business analytics report to accurately determine true drug utilization.

Launched Provenge, the first-in-class, autologous cellular immunotherapy for metastatic prostate cancer.

• 2013 Fast Start Patient Enrollment Competition: Ranked #2 of 103.
• 2012 National Commercial Excellence & Circle of Excellence Annual Awards. Sales ranking #1 of 103. 421% sales growth.
• Leadership Development: trained region on the paradigm shift of urologists referring patients to oncologists earlier so patients benefit.

Launched Treanda and promoted Trisenox, two novel hematology IV chemotherapies for CLL, iNHL & APL.

• 2009 National President's Club Winner (#4 of 92 colleagues).
• 2009 & 2008 Circle of Excellence award recipient.
• 2009 & 2008 South Central Area leader in sales volume.
• 2009 Treanda sales, 142% to goal & Trisenox sales, 220% to goal.
• 2010 Western Regional Trainer.
• 2010 Sales ranking (#2 South Central Area).

• Relaunched Ethyol/Amifostine to medical and radiation oncologists.
• Sales ranked #1 overall during my six year tenure.
• Crown Club winner, based on three time National CEO Club recipient years 2007, 2006 & 2004.
• 2006 OSS of the Year Award. Recipient of Top Ten Percent Awards: volume, percent to goal and growth.
• 2004 Promotion to senior oncology sales specialist.
• 2002-2007 Consistently performed over 100% to goal and increased sales year over year.
• Selected for 2003-05' national marketing/sales advisory and reimbursement committees.
• Leadership Development: Southwest region's reimbursement liaison.

The national leader in urological therapeutics, diagnostic clinical and anatomic pathology laboratory services.

• Increased region's Q2, 2001 revenues 50% verses Q2, 2000.
• National leader among five regions for pathology's highest average unit sale Ql‑Q2, 2001.
• Increased region's Q2, 2001 revenues 50% verses Q2, 2000.
• National leader among five regions for pathology's highest average unit sale Ql‑Q2, 2001.

Oncology Sales Specialist‑Nine States

• Promoted to launch ProstaSeed, UroCor's first therapeutic (brachytherapy) for prostate cancer.
• Co-promoted Casodex and Zoladex with Zeneca Pharmaceuticals.

National Account Manager-Seven States

• Directed long‑term strategic sales to gain managed care contracts in a highly capitated payor market.

Technical Sales Specialist – Dallas/Fort Worth

• Sales consultant with urologists concerning the pathological and clinical laboratory management of their prostate, bladder, and kidney stone diseased patients.
• Received 1998 national award for new product launch resulting in 1998 sales of $1,800,000.
• Ranked within the top 20% of 50 technical sales specialists.
• Secured contract for 17 Independent Physician Associations, contributing approximately $1,700,000.